Analystreport

Nektar Therapeutics (NKTR) is now covered by Wedbush. They set a "neutral" rating and a $70.00 price target on the stock.

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations